Biomarin Pharmaceutical Inc (BMRN): Daniel K Spiegelman , EVP, Chief Financial Officer of Biomarin Pharmaceutical Inc sold 1,649 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 8, 2016 to the Securities and Exchange Commission. The shares were sold at $89.14 per share for a total value of $146,991.86 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 2, 2016, Daniel K Spiegelman (EVP, Chief Financial Officer) sold 20,841 shares at $89.68 per share price.On May 31, 2016, Henry J Fuchs (EVP, Chief Medical Officer) sold 15,000 shares at $87.69 per share price.Also, On May 19, 2016, Robert Baffi (EVP, Technical Operations) sold 5,000 shares at $87.05 per share price.On May 10, 2016, George Eric Davis (EVP, General Counsel) sold 14,658 shares at $85.44 per share price.
Shares of BioMarin Pharmaceutical (BMRN) ended Tuesday, Jun 7, 2016 session in red amid volatile trading. The shares closed down -4.02 points or -4.49% at $85.5 with 11,81,620 shares getting traded. Post opening the session at $88.64, the shares hit an intraday low of $85.23 and an intraday high of $89.3 and the price vacillated in this range throughout the day. The company has a market cap of $13,879 M and the number of outstanding shares has been calculated to be 16,23,22,440 shares. The 52-week high of BioMarin Pharmaceutical is $151.75 and the 52-week low is $62.12.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha) Naglazyme (galsulfase) Kuvan (sapropterin dihydrochloride) Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States the European Union. Aldurazyme which was developed in collaboration with Genzyme Corporation (Genzyme) was approved for marketing in the United States the European Union and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).